antiviral agent 5

Antiviral agent 5 is a crucial intermediate utilized in the development of antiviral agents that specifically target 3C and 3CL proteases, which includes the SARS-CoV-2 M pro enzyme.

Antiviralagent 59 (compound 58) is a selective antiviral agent with drug-like properties, capable of inhibiting a broad spectrum of filoviruses. It demonstrates low off-target activity and inhibitory effects against replicative forms of Ebola virus (EBOV), Sudan virus (SUDV), and Marburg virus (MARV).

Antiviralagent 56 (Compound 4) is an antiviral agent with anti-HIV activity.

Antiviralagent 58 (Compound J1) is an orally active antiviral agent that exhibits broad-spectrum activity against enveloped viruses. It effectively targets various pathogens, including Influenza A virus (IAV), Respiratory Syncytial Virus (RSV), Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Human Coronavirus OC43 (HCoV-OC43), and Herpes Simplex Virus types 1 and 2 (HSV-1 and HSV-2).

Antiviralagent 57 (compound 81) is an antiviral drug that exhibits over 60% inhibition of ANO6 at a concentration of 50 nM.

Antiviral agent 51 (compound a), a potent fucoidan-based antiviral, interacts with DENV-2 RNA Dependant RNA polymerase (RdRp) [1].

1. Octyl Gallate is an antioxidant approved by the US Food and Drug Administration (FDA) as a food additive. 2. Octyl Gallate has antimetastatic activity. 3. Octyl Gallate shows antimicrobial activity against H. pylori, with a minimum inhibitory concentration (MIC) value of 125 ug mL. 4. Combination therapy with octyl gallate and ferulic acid improves cognition and neurodegeneration in a transgenic mouse model of Alzheimer's disease.5. Octyl Gallate is a potential anticancer agent, it exhibited decreased MCF-7 & MDA-MB-231 survival and induced apoptosis, with IC50 value of 40 uM. 6. Octyl gallate (Octyl 3,4,5-trihydroxybenzoate) has antiviral activity, it shows an inhibitory effect on the growth of herpes simplex virus type 1 (HSV-1) in HEp-2 or Vero cells. 7. Octyl gallate shows antifungal activity against Saccharomyces cerevisiae ATCC7754 and Zygosaccharomyces bailii ATCC 60483.

Retro-2 cycl is a dihydroquinazolinone (DHQZ) retrograde trafficking inhibitor. Retro-2 cycl (RN 1-001) inhibits JCPyV and HPV16 pseudovirus(IC50s of 54 μM and 160 μM, respectively),with antiviral agent.

(E)-5-(2-Bromovinyl)uracil (BVU) is a pyrimidine base and an inactive metabolite of the antiviral agents sorivudine and (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU), which can be regenerated to BVDU in vivo. BVU irreversibly inactivates dihydropyrimidine dehydrogenase (DPD) in an NADPH-dependent manner, enhancing the efficacy of the chemotherapeutic agent and DPD substrate 5-fluorouracil in a P388 murine leukemia model when administered at a dose of 200 μmol kg, thereby increasing survival time.

2-deoxy-D-Glucose-13C6is intended for use as an internal standard for the quantification of 2-deoxy-D-glucose by GC- or LC-MS. 2-deoxy-D-Glucose is a glucose antimetabolite and an inhibitor of glycolysis.1,2It inhibits hexokinase, the enzyme that converts glucose to glucose-6-phosphate, as well as phosphoglucose isomerase, the enzyme that converts glucose-6-phosphate to fructose-6-phosphate.32-deoxy-D-Glucose (16 mM) induces apoptosis in SK-BR-3 cells, as well as inhibits the growth of 143B osteosarcoma cells cultured under hypoxic conditions when used at a concentration of 2 mg ml.4,5In vivo, 2-deoxy-D-glucose (500 mg kg) reduces tumor growth in 143B osteosarcoma and MV522 non-small cell lung cancer mouse xenograft models when used alone or in combination with doxorubicin or paclitaxel .6 1.Kang, H.T., and Hwang, E.S.2-Deoxyglucose: An anticancer and antiviral therapeutic, but not any more a low glucose mimeticLife Sci.78(12)1392-1399(2006) 2.Aft, R.L., Zhang, F.W., and Gius, D.Evaluation of 2-deoxy-D-glucose as a chemotherapeutic agent: Mechanism of cell deathBr. J. Cancer87(7)805-812(2002) 3.Ralser, M., Wamelink, M.M., Struys, E.A., et al.A catabolic block does not sufficiently explain how 2-deoxy-D-glucose inhibits cell growthProc. Natl. Acad. Sci. USA105(46)17807-17811(2008) 4.Liu, H., Savaraj, N., Priebe, W., et al.Hypoxia increases tumor cell sensitivity to glycolytic inhibitors: A strategy for solid tumor therapy (Model C)Biochem. Pharmacol.64(12)1745-1751(2002) 5.Zhang, X.D., Deslandes, E., Villedieu, M., et al.Effect of 2-deoxy-D-glucose on various malignant cell lines in vitroAnticancer Res.26(5A)3561-3566(2006) 6.Maschek, G., Savaraj, N., Priebe, W., et al.2-deoxy-D-glucose increases the efficacy of adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancers in vivoCancer Res.64(1)31-34(2004)

(-)-5′-Noraristeromycin is an antiviral agent and enantiomer of 5'-noraristeromycin that inhibits intracellular HBV replication and virion production, and can be used in cancer research[1].

Antiviral agent 18 (Compound 5) demonstrates significant antiviral activity against murine norovirus and holds potential for research in infectious and malignant diseases [1].

L-I-OddU, a potent and selective anti-Epstein-Barr virus (EBV) agent, is a L-5'-halo-dioxolane nucleoside analogue. It demonstrates antiviral activity by effectively suppressing replicative EBV DNA and viral protein synthesis [1] [2]. With an EC 50 value of 0.03 μM, L-I-OddU exhibits high potency against EBV while maintaining low cytotoxicity, as indicated by its CC 50 value of 1000 nM.

TMV-IN-5 (compound 1a) is an antiviral and antifungal agent that inhibits the assembly of the tobacco mosaic virus (TMV) by binding to its coat protein (CP), making it a potential candidate for pesticide formulations [1].

BVDU 5′-Triphosphate is an antiviral agent labeled with 5′-Triphosphate that specifically targets viral DNA polymerase. It exhibits outstanding selectivity for varicella-zoster virus (VZV) and herpes simplex virus type 1 (HSV-1) owing to its phosphorylation by the virus-specific thymidine kinase.

XSJ2-46, a 5'-amino NI analog, is an antiviral agent possessing anti-Zika virus properties and demonstrates reasonable inhibition of RNA-dependent RNA polymerases (RdRp), with an IC50 of 8.78 μM [1].

EBOV-IN-5 (compound 14) serves as an antiviral agent targeting the Ebola virus (EBOV) by disrupting its entry mechanism into host cells. It specifically blocks the interaction between the EBOV glycoprotein EBOV-GPcl and the essential host receptor NPC1, which is crucial for the virus's fusion and entry into the cell. [7] [1]

EV-A71-IN-2 (compound 6c) is an antiviral agent targeting Enterovirus A71, exhibiting EC50 values of 0.29 μM in EV-A71-MRC-5 cells and 1.66 μM in EV-A71-RD cells. It is utilized in research focused on Enterovirus infections.

DNA polymerase-IN-5 (compound 42) is a broad-spectrum antiviral agent effective against herpesviruses. It exhibits inhibitory activity against CMV and VZV with IC50 values of 6.6 μM and 4.8 μM, respectively.

Nucleoside Derivatives - 5-Modified pyrimidine nucleosides; Azido-nucleosides; 2',3'-Dideoxy nucleosides; Drugs and Inhibitors; Antiviral agent